Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ELI LILLY & CoLLY · Entity 2794 | SVP&Pres, LillyDiab & LillyUSA | February 04, 2019 | February 20, 2019 |
| KYNTRA BIO, INC.FGEN · Entity 7431 | Director · Chief Executive Officer | July 07, 2023 | July 10, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ELI LILLY & Co
Report date February 04, 2019 · Filed February 20, 2019 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 157,962 |
Reported balance
After 2019-02-04 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2019-02-04 · Grant · Acquired 26,682 · Balance 157,962 F1: This amendment is being filed to correctly report the amount acquired in column 4, and to correct the number of securities beneficially owned following the reported transaction, as reported in column 5. |
Filing footnotes · ownership attribution and instrument terms
F1: This amendment is being filed to correctly report the amount acquired in column 4, and to correct the number of securities beneficially owned following the reported transaction, as reported in column 5.
KYNTRA BIO, INC.
Report date July 07, 2023 · Filed July 10, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 374,722 |
Reported balance
After 2023-07-07 transaction · row 1
1 source rowRow 1 · 2023-07-07 · Sale · Disposed 1,880 · Balance 374,722 F1: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 27,800 |
Reported balance
Holding disclosure · report date 2023-07-07 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 27,800 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 01, 2017 Filed Feb 3, 2017 19:35 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 10,244 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000062 · wf-form4_148615054513386.xml · derivative · entry 4 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,244 shares Expires 2017-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 19:35 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 4,810 | $77.03 | $370,514.30 |
DisclosureSEC source: 0000059478-17-000062 · wf-form4_148615054513386.xml · nonDerivative · entry 2 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,217 Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 19:35 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 10,244 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000062 · wf-form4_148615054513386.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,027 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 22:51 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantRestricted Stock Unit · Derivative | 21,326 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000028 · wf-form4_148590304851291.xml · derivative · entry 3 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,326 Underlying: Common Stock · 21,326 shares Expires 2018-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 22:51 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 20,211 | $75.38 | $1,523,505.18 |
DisclosureSEC source: 0000059478-17-000028 · wf-form4_148590304851291.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,783 Read SEC document |
| February 01, 2016 Filed Feb 3, 2016 18:46 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 10,360 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-16-000290 · wf-form4_145452516192048.xml · derivative · entry 4 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,360 shares Expires 2016-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2016 Filed Feb 3, 2016 18:46 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 4,872 | $79.10 | $385,375.20 |
DisclosureSEC source: 0000059478-16-000290 · wf-form4_145452516192048.xml · nonDerivative · entry 2 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,572 Read SEC document |
| February 01, 2016 Filed Feb 3, 2016 18:46 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 10,360 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-16-000290 · wf-form4_145452516192048.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,444 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2016 Filed Jan 28, 2016 23:45 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantRestricted Stock Unit · Derivative | 10,244 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-16-000269 · wf-form4_145402468774587.xml · derivative · entry 3 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,244 Underlying: Common Stock · 10,244 shares Expires 2017-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 26, 2016 Filed Jan 28, 2016 23:45 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 19,953 | $81.96 | $1,635,347.88 |
DisclosureSEC source: 0000059478-16-000269 · wf-form4_145402468774587.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,084 Read SEC document |
| December 09, 2015 Filed Dec 10, 2015 19:09 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 25,000 | $83.88 | $2,097,000.00 |
DisclosureSEC source: 0000059478-15-000225 · wf-form4_144977454120447.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,131 F1 · price: This transaction was executed in multiple trades at prices ranging from $83.66 to $84.05. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 12, 2015 Filed Nov 16, 2015 20:51 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionEmployee stock option 2/06 (right to buy) · Derivative | 6,928 | $0.00 Strike: $56.18 | $0.00 |
DisclosureSEC source: 0000059478-15-000193 · wf-form4_144770710752228.xml · derivative · entry 4 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,928 shares Expires 2016-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 12, 2015 Filed Nov 16, 2015 20:51 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 5,579 | $80.70 | $450,225.30 |
DisclosureSEC source: 0000059478-15-000193 · wf-form4_144770710752228.xml · nonDerivative · entry 2 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,131 Read SEC document |
| November 12, 2015 Filed Nov 16, 2015 20:51 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 6,928 | $56.18 | $389,215.04 |
DisclosureSEC source: 0000059478-15-000193 · wf-form4_144770710752228.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,710 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2015 Filed Feb 3, 2015 20:50 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 13,990 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-15-000050 · wf-form4_142299663670511.xml · derivative · entry 4 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,990 shares Expires 2015-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2015 Filed Feb 3, 2015 20:50 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 6,608 | $72.00 | $475,776.00 |
DisclosureSEC source: 0000059478-15-000050 · wf-form4_142299663670511.xml · nonDerivative · entry 2 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,782 Read SEC document |
| February 01, 2015 Filed Feb 3, 2015 20:50 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 13,990 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-15-000050 · wf-form4_142299663670511.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,390 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 22:12 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantRestricted Stock Unit · Derivative | 10,360 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-15-000020 · wf-form4_142265593700407.xml · derivative · entry 3 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,360 Underlying: Common Stock · 10,360 shares Expires 2016-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 22:12 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 30,037 | $70.97 | $2,131,725.89 |
DisclosureSEC source: 0000059478-15-000020 · wf-form4_142265593700407.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,400 Read SEC document |
| December 10, 2014 Filed Dec 12, 2014 22:06 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionEmployee stock option 2/05 (right to buy) · Derivative | 7,101 | $0.00 Strike: $55.65 | $0.00 |
DisclosureSEC source: 0000059478-14-000222 · wf-form4_141842196908039.xml · derivative · entry 4 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,101 shares Expires 2015-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 10, 2014 Filed Dec 12, 2014 22:06 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 6,046 | $72.21 | $436,581.66 |
DisclosureSEC source: 0000059478-14-000222 · wf-form4_141842196908039.xml · nonDerivative · entry 2 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,791 Read SEC document |
| December 10, 2014 Filed Dec 12, 2014 22:06 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 7,101 | $55.65 | $395,170.65 |
DisclosureSEC source: 0000059478-14-000222 · wf-form4_141842196908039.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,837 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 10, 2014 Filed Dec 16, 2014 21:04 UTC Amendment | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 5,474 | $72.21 | $395,277.54 |
DisclosureSEC source: 0000059478-14-000226 · wf-form4a_141876386481023.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,363 F1 · shares: This amendment is being filed to correctly report the amount disposed in column 4, and to correct the number of securities beneficially owned following the reported transaction, as reported in column 5. F1 · balance_after: This amendment is being filed to correctly report the amount disposed in column 4, and to correct the number of securities beneficially owned following the reported transaction, as reported in column 5. Read SEC document |
| November 03, 2014 Filed Nov 4, 2014 20:08 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 5,000 | $66.03 | $330,150.00 |
DisclosureSEC source: 0000059478-14-000181 · wf-form4_141513169758618.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,736 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 29, 2014. Read SEC document |
| October 01, 2014 Filed Oct 3, 2014 15:12 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 5,000 | $64.86 | $324,300.00 |
DisclosureSEC source: 0000059478-14-000157 · wf-form4_141234916007183.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,736 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 29, 2014. F2 · price: This transaction was executed in multiple trades at prices ranging from $64.75 to $65.06. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 02, 2014 Filed Sep 3, 2014 15:42 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 5,000 | $63.60 | $318,000.00 |
DisclosureSEC source: 0000059478-14-000147 · wf-form4_140975896339125.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,736 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 29, 2014. Read SEC document |
| July 25, 2014 Filed Jul 28, 2014 19:16 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 10,000 | $63.79 | $637,900.00 |
DisclosureSEC source: 0000059478-14-000133 · wf-form4_140657495079866.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,736 F1 · price: This transaction was executed in multiple trades at prices ranging from $63.72 to $63.84. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 01, 2014 Filed Feb 4, 2014 15:25 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 15,674 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000059 · wf-form4_139152754455047.xml · derivative · entry 4 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,674 shares Expires 2014-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2014 Filed Feb 4, 2014 15:25 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 7,363 | $54.01 | $397,675.63 |
DisclosureSEC source: 0000059478-14-000059 · wf-form4_139152754455047.xml · nonDerivative · entry 2 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,736 Read SEC document |
| February 01, 2014 Filed Feb 4, 2014 15:25 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 15,674 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000059 · wf-form4_139152754455047.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,099 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 28, 2014 Filed Jan 31, 2014 01:29 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantRestricted Stock Unit · Derivative | 13,990 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000028 · wf-form4_139113177496754.xml · derivative · entry 3 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,990 Underlying: Common Stock · 13,990 shares Expires 2015-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 28, 2014 Filed Jan 31, 2014 01:29 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 32,248 | $54.23 | $1,748,809.04 |
DisclosureSEC source: 0000059478-14-000028 · wf-form4_139113177496754.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,425 Read SEC document |
| August 15, 2013 Filed Aug 16, 2013 15:18 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 5,000 | $53.79 | $268,950.00 |
DisclosureSEC source: 0001209191-13-041072 · doc4.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,177 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2013. Read SEC document |
| July 15, 2013 Filed Jul 15, 2013 20:23 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 5,000 | $51.43 | $257,150.00 |
DisclosureSEC source: 0001209191-13-036637 · doc4.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,177 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2013. Read SEC document |
| June 17, 2013 Filed Jun 18, 2013 14:34 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 5,000 | $52.45 | $262,250.00 |
DisclosureSEC source: 0001209191-13-032601 · doc4.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,177 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2013. Read SEC document |
| May 15, 2013 Filed May 16, 2013 20:06 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 5,000 | $56.15 | $280,750.00 |
DisclosureSEC source: 0001209191-13-026800 · doc4.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,177 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2013. Read SEC document |
| May 01, 2013 Filed May 1, 2013 19:46 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 10,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-023302 · doc4.xml · derivative · entry 4 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2013-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2013 Filed May 1, 2013 19:46 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 4,698 | $55.38 | $260,175.24 |
DisclosureSEC source: 0001209191-13-023302 · doc4.xml · nonDerivative · entry 2 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,177 Read SEC document |
| May 01, 2013 Filed May 1, 2013 19:46 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-023302 · doc4.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 15, 2013 Filed Apr 16, 2013 15:46 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 5,000 | $57.10 | $285,500.00 |
DisclosureSEC source: 0001209191-13-021441 · doc4.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,875 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2013. F2 · price: This transaction was executed in multiple trades at prices ranging from $57.09 to $57.14. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 01, 2013 Filed Feb 4, 2013 21:23 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 31,768 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-005976 · doc4.xml · derivative · entry 4 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 31,768 shares Expires 2013-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2013 Filed Feb 4, 2013 21:23 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 14,922 | $53.69 | $801,162.18 |
DisclosureSEC source: 0001209191-13-005976 · doc4.xml · nonDerivative · entry 2 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,875 Read SEC document |
| February 01, 2013 Filed Feb 4, 2013 21:23 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 31,768 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-005976 · doc4.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,797 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 25, 2013 Filed Jan 29, 2013 22:00 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantRestricted Stock Unit · Derivative | 15,674 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-005008 · doc4.xml · derivative · entry 3 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,674 Underlying: Common Stock · 15,674 shares Expires 2014-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 25, 2013 Filed Jan 29, 2013 22:00 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 33,017 | $53.21 | $1,756,834.57 |
DisclosureSEC source: 0001209191-13-005008 · doc4.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,029 Read SEC document |
| August 01, 2012 Filed Aug 1, 2012 19:13 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 5,000 | $44.16 | $220,800.00 |
DisclosureSEC source: 0001209191-12-039819 · doc4.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,012 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 12, 2012. Read SEC document |
| July 02, 2012 Filed Jul 3, 2012 19:34 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 5,000 | $43.00 | $215,000.00 |
DisclosureSEC source: 0001209191-12-036813 · doc4.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,012 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 12, 2012. Read SEC document |
| June 01, 2012 Filed Jun 4, 2012 19:52 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 5,000 | $40.60 | $203,000.00 |
DisclosureSEC source: 0001209191-12-031898 · doc4.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,012 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 12, 2012. Read SEC document |
| May 01, 2012 Filed May 2, 2012 14:09 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 5,000 | $41.32 | $206,600.00 |
DisclosureSEC source: 0001209191-12-025306 · doc4.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,012 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 12, 2012. Read SEC document |
| April 02, 2012 Filed Apr 4, 2012 17:37 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 5,000 | $40.30 | $201,500.00 |
DisclosureSEC source: 0001209191-12-021779 · doc4.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,012 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 12, 2012. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.